Dipharma completes acquisition of Kalexsyn 24th May 2018
Dipharma, a Baranzate, Italy-headquartered active pharmaceutical ingredients manufacturer, has completed its previously announced acquisition of Kalexsyn, a Kalamazoo, Michigan-headquartered contract research organization (CRO) providing chemistry services to the biotechnology and pharmaceutical industry. Dipharma announced the acquisition in April 2018.
Founded in 2003 by Robert Gadwood and David Zimmermann, Kalexsyn provides chemistry services that primarily support the drug-discovery activities of their customers. These services include custom synthesis, stable label synthesis, process impurity synthesis, and process route-improvement work. Kalexsyn employs synthetic organic chemists with experience in drug-discovery and process development.
Pursuant to the companies’ agreement, Dipharma acquired all of the issued and outstanding shares of Kalexsyn through its US subsidiary Dipharma, Inc.